Detalles de la búsqueda
1.
Transitions of blood immune endotypes and improved outcome by anakinra in COVID-19 pneumonia: an analysis of the SAVE-MORE randomized controlled trial.
Crit Care
; 28(1): 73, 2024 03 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-38475786
2.
Interferon gamma-induced protein 10 (IP-10) for the early prognosis of the risk for severe respiratory failure and death in COVID-19 pneumonia.
Cytokine
; 162: 156111, 2023 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-36529030
3.
Efficacy and safety of early soluble urokinase plasminogen receptor plasma-guided anakinra treatment of COVID-19 pneumonia: A subgroup analysis of the SAVE-MORE randomised trial.
EClinicalMedicine
; 56: 101785, 2023 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-36590789
4.
Development and validation of SCOPE score: A clinical score to predict COVID-19 pneumonia progression to severe respiratory failure.
Cell Rep Med
; 3(3): 100560, 2022 03 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-35474750
5.
Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial.
Nat Med
; 27(10): 1752-1760, 2021 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-34480127
6.
Erlotinib-Associated Rash in Advanced Non-Small Cell Lung Cancer: Relation to Clinicopathological Characteristics, Treatment Response, and Survival.
Oncol Res
; 26(1): 59-69, 2018 Jan 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-28390118
7.
Author Correction: Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial.
Nat Med
; 27(10): 1850, 2021 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-34625750
Resultados
1 -
7
de 7
1
Próxima >
>>